Toxic and drug-induced peripheral neuropathies: Updates on causes, mechanisms and management

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 481-488

  Diezi, Manuel ^a   Buclin, Thierry ^b   Kuntzer, Thierry ^c  

^a Division of Clinical Pharmacology   (Switzerland)

^b Hemato oncology Unit   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADALIMUMAB; ALPHA TOCOPHEROL; AMIFOSTINE; ANANDAMIDE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CALMODULIN INHIBITOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; EPOTHILONE DERIVATIVE; ETANERCEPT; GABAPENTIN; INFLIXIMAB; ION CHANNEL; IXABEPILONE; MELATONIN; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLESOXIME; OXALIPLATIN; PACLITAXEL; PREGABALIN; PROPENTOFYLLINE; SILIBININ; SORAFENIB; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

APOPTOSIS; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; DRUG INDUCED DISEASE; DRUG INDUCED PERIPHERAL NEUROPATHY; EARLY DIAGNOSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; HYPERALGESIA; IN VIVO STUDY; INFLAMMATION; LASER DOPPLER FLOWMETRY; MITOCHONDRIAL TOXICITY; MOTOR NERVE; NERVE FIBER; NONHUMAN; OXIDATIVE STRESS; PATIENT ASSESSMENT; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; POLYRADICULONEUROPATHY; QUALITY OF LIFE; REVIEW; SCHWANN CELL; SENSORY NERVE; SPINAL GANGLION;

ANIMALS; DISEASE MODELS, ANIMAL; EARLY DIAGNOSIS; HUMANS; INFLAMMATION; PAIN; PAIN MANAGEMENT; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84883828827     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328364eb07     Document Type: Review

References (94)

1. Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: From clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011; 10:407-417.
2. Johnson DC, Corthals SL, Walker BA, et al.Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011; 29:797-804.
3. Saifee TA, Elliott KJ, Rabin N, et al. Bortezomib-induced inflammatory neuropathy. J Peripher Nerv Syst 2010; 15:366-368.
4. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010; 11:1057-1065.
5. Kim HJ, Oh GS, Lee JH, et al. Cisplatin ototoxicity involves cytokines and STAT6 signaling network. Cell Res 2011; 21:944-956.
6. Materazzi S, Fusi C, Benemei S, et al. TRPA1 and TRPV4 mediate paclitaxelinduced peripheral neuropathy in mice via a glutathione-sensitive mechanism. Pflugers Arch 2012; 463:561-569.
7. Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: Effects on NF-kappaB and Nrf2 cascades. J Pineal Res 2011; 50:124-131.
8. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011; 2011:843019.
9. Zheng X, Ouyang H, Liu S, et al. TNFalpha is involved in neuropathic pain induced by nucleoside reverse transcriptase inhibitor in rats. Brain Behav Immun 2011; 25:1668-1676.
10. Spicarova D, Nerandzic V, Palecek J. Modulation of spinal cord synaptic activity by tumor necrosis factor alpha in a model of peripheral neuropathy. J Neuroinflamm 2011; 8:177.
11. Renard D, Gauthier T, Venetz J-P, et al. Late onset tacrolimus-induced lifethreatening polyneuropathy in a kidney transplant recipient patient. Clin Kidney J 2012; 5:323-326.
12. Shemesh OA, Spira ME. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: Implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 2010; 119:235-248.
13. Xiao WH, Zheng H, Zheng FY, et al. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat. Neuroscience 2011; 199:461-469.
14. Xiao WH, Bennett GJ. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012; 153:704-709.
15. Stubblefield MD, Vahdat LT, Balmaceda CM, et al. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clin Oncol 2005; 17:271-276.
16. Argyriou AA, Kalofonos HP. Vitamin E for preventing chemotherapy-induced peripheral neuropathy. Support Care Cancer 2011; 19:725-726. [author reply 727-728]
17. Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial. Support Care Cancer 2011; 19:1769-1777.
18. Ledeboer A, Hutchinson MR, Watkins LR, et al. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 2007; 16:935-950.
19. Cervellini I, Bello E, Frapolli R, et al. The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. Neurotox Res 2010; 18:151-160.
20. Xiao WH, Zheng FY, Bennett GJ, et al. Olesoxime (cholest-4-en-3-one, oxime): Analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain 2009; 147:202-209.
21. Wang X-M, Lehky TJ, Brell JM, et al. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012; 59:3-9.
22. Di Cesare Mannelli L, Zanardelli M, Failli P, et al. Oxaliplatin-induced neuropathy: Oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain 2012; 13:276-284.
23. Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012; 203:194-206.
24. Opii WO, Sultana R, Abdul HM, et al. Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2',3'- dideoxycytidine (ddC): Relevance to HIV-dementia. Exp Neurol 2007; 204:29-38.
25. Garrido JJ. Vascular endothelial growth factor and HDAC 6: A neuroprotective signalling pathway against cancer therapy-induced neuropathy. Brain 2012; 135 (Pt 9):2579-2580.
26. Verheyen A, Peeraer E, Nuydens R, et al. Systemic antivascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain 2012; 135 (Pt 9):2629-2641.
27. Bujalska M, Makulska-Nowak H. Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model. Neuro Endocrinol Lett 2009; 30:144-152.
28. Sweitzer SM, Pahl JL, DeLeo JA. Propentofylline attenuates vincristineinduced peripheral neuropathy in the rat. Neurosci Lett 2006; 400:258-261.
29. Argyriou AA, Marmiroli P, Cavaletti G, et al. Epothilone-induced peripheral neuropathy: A review of current knowledge. J Pain Symptom Manage 2011; 42:931-940.
30. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A 2012; 109:6704-6709.
31. Berger JV, Knaepen L, Janssen SP, et al. Cellular and molecular insights into neuropathy-induced pain hypersensitivity for mechanism-based treatment approaches. Brain Res Rev 2011; 67:282-310.
32. Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol 2012; 82:51-77.
33. Ishibashi K, Okada N, Miyazaki T, et al. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol 2010; 15:82-87.
34. Scott RH, Woods AJ, Lacey MJ, et al. An electrophysiological investigation of the effects of cisplatin and the protective actions of dexamethasone on cultured dorsal root ganglion neurones from neonatal rats. Naunyn Schmiedebergs Arch Pharmacol 1995; 352:247-255.
35. Nodera H, Spieker A, Sung M, et al. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. Neurosci Lett 2011; 505:223-227.
36. Kagiava A, Tsingotjidou A, Emmanouilides C, et al. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology 2008; 29:1100-1106.
37. Dimitrov AG, Dimitrova NA. A possible link of oxaliplatin-induced neuropathy with potassium channel deficit. Muscle Nerve 2012; 45:403-411.
38. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012; 291:1-9.
39. Kawakami K, Chiba T, Katagiri N, et al. Paclitaxel increases high voltagedependent calcium channel current in dorsal root ganglion neurons of the rat. J Pharmacol Sci 2012; 120:187-195.
40. Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 2011; 193:440-451.
41. Nassini R, Gees M, Harrison S, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011; 152:1621-1631.
42. Ta LE, Bieber AJ, Carlton SM, et al. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010; 6:15.
43. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not Fas receptor signaling. Neurobiol Dis 2002; 9:220-233.
44. Hsu CK, Chen YQ, Lung VZ, et al. Myelopathy and polyneuropathy caused by nitrous oxide toxicity: A case report. Am J Emerg Med 2012; 30:1016; e3-6.
45. Stubgen JP. Drug-induced dysimmune demyelinating neuropathies. J Neurol Sci 2011; 307:1-8.
46. Yoon JY, Nam TS, Kim MK, et al. Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy. Asia Pac J Clin Oncol 2012; 8:201-204.
47. Camdessanche JP, Jousserand G, Franques J, et al. A clinical pattern-based etiological diagnostic strategy for sensory neuronopathies: A French collaborative study. J Peripher Nerv Syst 2012; 17:331-340.
48. Chopra K, Tiwari V. Alcoholic neuropathy: Possible mechanisms and future treatment possibilities. Br J Clin Pharmacol 2012; 73:348-362.
49. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neuro-oncology 2012; 14 (Suppl 4):iv45-54.
50. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer. Cancer 2013; 119:438-444.
51. Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: From consensus to the first validity and reliability findings. Ann Oncol 2013; 24:454-462.
52. Kautio AL, Haanpaa M, Kautiainen H, et al. Burden of chemotherapy-induced neuropathy: A cross-sectional study. Support Care Cancer 2011; 19:1991-1996.
53. Kautio A-L, Haanpaa M, Kautiainen H, et al. Oxaliplatin scale and National Cancer Institute: Common toxicity criteria in the assessment of chemotherapyinduced peripheral neuropathy. Anticancer Res 2011; 31:3493-3496.
54. Bentzen AG, Balteskard L, Wanderas EH, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors. Acta Oncol 2013; 52:736-744.
55. Stubblefield MD, McNeely ML, Alfano CM, et al. A prospective surveillance model for physical rehabilitation of women with breast cancer: Chemotherapyinduced peripheral neuropathy. Cancer 2012; 118 (8 Suppl):2250-2260.
56. Baxter CG, Marshall A, Roberts M, et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother 2011; 66: 2136-2139.
57. Tolaney SM, Najita J, Sperinde J, et al. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 2013; 24:1841-1847.
58. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381:1203-1210.
59. Palmer M, Chersich M, Moultrie H, et al. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in Soweto, South Africa. AIDS 2013; 27:781-785.
60. Shimizu T, Yokoi T, Tamaki T, et al. Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced nonsmall cell lung cancer. Oncol Lett 2013; 5:761-767.
61. Anter AH, Abdel-Latif RM. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: Phase II trial. Med Oncol 2013; 30:451.
62. Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009; 66:490-497.
63. Lauria G, Merkies IS, Faber CG. Small fibre neuropathy. Curr Opin Neurol 2012; 25:542-549.
64. Tan IL, Polydefkis MJ, Ebenezer GJ, et al. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012; 69:265-268.
65. Merkies IS, Lauria G, Faber CG. Outcome measures in peripheral neuropathies: Requirements through statements. Curr Opin Neurol 2012; 25:556-563.
66. Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 2011; 16:228-236.
67. Driessen CML, de Kleine-Bolt KME, Vingerhoets AJJM, et al. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: The introduction of a new measure. Support Care Cancer 2012; 20:877-881.
68. Park SB, Lin CS, Kiernan MC. Nerve excitability assessment in chemotherapyinduced neurotoxicity. J Vis Exp 2012. [Epub ahead of print]
69. Namer B, Pfeffer S, Handwerker HO, et al. Axon reflex flare and quantitative sudomotor axon reflex contribute in the diagnosis of small fiber neuropathy. Muscle Nerve 2013; 47:357-363.
70. Authier N, Balayssac D, Marchand F, et al. Animal models of chemotherapyevoked painful peripheral neuropathies. Neurotherapeutics 2009; 6:620-629.
71. Bruna J, Ale A, Velasco R, et al. Evaluation of preexisting neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. J Peripher Nerv Syst 2011; 16:199-212.
72. Khasabova IA, Khasabov S, Paz J, et al. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012; 32: 7091-7101.
73. Bhattacharya MR, Gerdts J, Naylor SA, et al. A model of toxic neuropathy in Drosophila reveals a role for MORN4 in promoting axonal degeneration. J Neurosci 2012; 32:5054-5061.
74. Schellingerhout D, LeRoux LG, Hobbs BP, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One 2012; 7:e45776.
75. Shiga K, Tanaka E, Isayama R, et al. Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon alpha-2b: A neuropathology case report. Intern Med 2012; 51:217-221.
76. Mir O, Alexandre J, Tran A, et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: Clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009; 20:736-740.
77. Nodera H, Rutkove SB. Long-term nerve excitability changes by persistent Na+ current blocker ranolazine. Neurosci Lett 2012; 524:101-106.
78. Suter MR, Kirschmann G, Laedermann CJ, et al. Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology 2013; 118:160-172.
79. Kagiava A, Kosmidis EK, Theophilidis G. Oxaliplatin-induced hyperexcitation of rat sciatic nerve fibers: An intra-axonal study. Anticancer Agents Med Chem 2013; 13:373-379.
80. Schulze C, McGowan M, Jordt SE, et al. Prolonged oxaliplatin exposure alters intracellular calcium signaling: A new mechanism to explain oxaliplatin-associated peripheral neuropathy. Clin Colorectal Cancer 2011; 10:126-133.
81. Nilius B, Appendino G, Owsianik G. The transient receptor potential channel TRPA1: From gene to pathophysiology. Pflugers Arch 2012; 464:425-458.
82. Nilius B, Honore E. Sensing pressure with ion channels. Trends Neurosci 2012; 35:477-486.
83. Chester AC, Sandroni P. Case report: Peripheral polyneuropathy and mefloquine prophylaxis. Am J Trop Med Hyg 2011; 85:1008-1009.
84. Milatovic D, Jenkins JW, Hood JE, et al. Mefloquine neurotoxicity is mediated by nonreceptor tyrosine kinase. Neurotoxicology 2011; 32:578-585.
85. Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006; 42:2893-2896.
86. Sissung TM, Baum CE, Deeken J, et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 2008; 14:4543-4549.
87. Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56:361-367.
88. Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007; 27:9451-9457.
89. Favis R, Sun Y, van de Velde H, et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genom 2011; 21:121-129.
90. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009; 8:10-16.
91. Arrieta O, Hernandez-Pedro N, Fernandez-Gonzalez-Aragon MC, et al. Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology 2011; 77:987-995.
92. Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2011; CD005228.
93. Weber B, Largillier R, Ray-Coquard I, et al. A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: A prospective phase II GINECO trial. Support Care Cancer 2013; 21: 1947-1954.
94. Costa R, Motta EM, Dutra RC, et al. Antinociceptive effect of kinin B(1) and B(2) receptor antagonists on peripheral neuropathy induced by paclitaxel in mice. Br J Pharmacol 2011; 164:681-693.